Emergency reversal of anticoagulation: Novel agents

Current Neurology and Neuroscience Reports

Volumn 14, Issue 8, 2014, Pages

  Levine, Michael ^a   Goldstein, Joshua N ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticoagulants; Coagulopathy; Direct thrombin inhibitors; Factor Xa inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FONDAPARINUX; FRESH FROZEN PLASMA; IDRAPARINUX; KANOKAD; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN; ANTITHROMBIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG USE; EMERGENCY TREATMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; NONHUMAN; PUBLICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; FACTOR XA INHIBITORS; HUMANS;

EID: 84902891176     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0471-7     Document Type: Article

References (49)

1. De Caterina R, Husted S, Wallentin L, et al. Generalmechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC working group on thrombosis-task force on anticoagulants in heart disease Thromb Haemost. 2013;109:569-79.
2. Dahlback B. Blood coagulation Lancet. 2000;355:1627-32. (Pubitemid 30240513)
3. Wheeler AP, Rice TW. Coagulopathy in critically ill patients: Part 2 - soluble clotting factors and hemostatic testing. Chest. 2010;137:185-94.
4. Vine AK. Recent advances in haemostasis and thrombosis. Retina. 2009;29:1-7.
5. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108:1147-52.
6. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway and blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687-93. (Pubitemid 47207163)
7. Davi G, Patrono C. Platelet activation and thrombosis. N Engl J Med. 2007;357:2482-94.
8. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1Suppl):8S-21S. (Pubitemid 32154192)
9. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;247:541-4. (Pubitemid 38209111)
10. Garcia D, Barrett YC, Ramacciotti E, et al. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11:242-52.
11. .• Yee DL, O'Brien SH, Young G. The pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013;52:967-80. This review by Yee et al. provides an in-depth review of the pharmacologic properties of several of the newer anticoagulants.
12. Ageno W, Gallus AS, Wittkowsky A, et al. Antithrombotic therapy and prevention of thrombosis, 9th edition. American College of Chest Physicians evidence-based clinical practice guidelines Chest. 2012;141(Suppl):e44S-88S.
13. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581-92.
14. Prescribing information. Boehringer Ingelheim Pharmaceuticals. Pradaxa. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet. ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/ Pradaxa.pdf. Accessed 7 April 2014.
15. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436-50.
16. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with two doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. 2011;123:2363-72.
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
18. • Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281-7. Ganetsky and colleagues provide an in-depth review of dabigatran, and review strategies that are and are not likely to be effective in reversal of the anticoagulation effects of dabigatran.
19. Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost. 2013;110:308-15.
20. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-43.
21. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
22. Bowry R, Fraser S, Archeval-Lao JM, et al. Thromboelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke. 2014;45:880-3.
23. Kawano-Castillo J, Ward E, Elliott A, et al. Thromboelastography detects possible coagulation disturbance in patients with intracerebral hemorrhage with hematoma enlargement. Stroke. 2014;45: 683-8.
24. Anonymous. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int. 2013;22:155-9.
25. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011;124:1508-10.
26. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
27. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Heaemost. 2012;10:1841-8.
28. Schiele F, Van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;18:3554-62.
29. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-9.
30. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9.
31. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-24.
32. Dinkelaar J, Molenaar PJ, Ninivaggi M, et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost. 2013;11:1118-8.
33. • Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Col Cardiol. 2011;57: 1330-7. This guideline is from a widely respected group that examines the evidence base for the management and reversal of dabigatran.
34. •• Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Haematol. 2012;87 Suppl 1:S141-5. This paper discusses important reversal strategies of both the oral direct thrombin inhibitors, as well as the factor Xa inhibitors.
35. •• Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs) apixaban, dabigatran, and rivaroxaban. Clin Res Cardiol. 2013;102:399-412. This paper discusses important reversal strategies of both the oral direct thrombin inhibitors, as well as the factor Xa inhibitors.
36. •• Rybinnik I, Mullen MT, Messe S, et al. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. J Stroke Cerebrovasc Dis. 2013;22:1312-6. This paper demonstrates the wide variety of practice strategies being used in current clinical care.
37. Baumann Kreuziger LM, Reding MT. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thromb Res. 2013;132:e161-3.
38. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24:2757-65.
39. Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res. 2012;111:1069-78.
40. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010;70:2153-70.
41. Prescribing information. Bristol-Myers Squibb Company. Eliquis. Available at: http://packageinserts.bms.com/pi/pi-eliquis.pdf. Accessed 7 April 2014.
42. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
43. Bhanwra S, Ahluwalia K. The new factor Xa inhibitor: apixaban. J Pharmacol Pharmacother. 2014;5:12-4.
44. Prescribing information. Janssen Pharmaceuticals. Xarelto. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf#zoom=100. Accessed 7 April 2014.
45. Gresham C, Levine M, Ruha AM. Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose. J Med Toxicol. 2009;5:242-9.
46. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. The effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-9.
47. Martin AC, LeBonniec B, Fischer AM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168:4228-33.
48. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116:94-102.
49. Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107:253-9.